Profusa has partnered with MedSell to commercialize its Lumee™ Oxygen tissue monitoring device in France, expanding its existing footprint across Spain, Germany, the Benelux countries, Austria, the United Kingdom and Scandinavia. This new agreement brings the total annual critical limb ischemia (CLI) cases addressable by its European distributor network to approximately 200,000, and leverages MedSell’s tailored market-entry and clinical support services in both hospital and outpatient settings. The collaboration also complements a key opinion leader agreement with Professor Yann Gouëffic at Groupe Hospitalier Paris Saint Joseph, whose practice accounts for about 8% of France’s CLTI cases and will support clinical studies of home monitoring applications.

Profusa’s management forecasts potential revenue of $0.5 million to $2 million in 2026 as commercial launch in Europe begins in the second quarter, rising to $9 million to $13 million in 2027 with planned expansion into the U.S. market. Looking further ahead, the company targets $200 million to $250 million in annual revenue by 2030, driven by adoption of its tissue-integrated biosensor platform across vascular surgery, wound care and chronic disease management. Recent presentations of U.S. clinical trial data at major European vascular conferences have further validated the technology’s utility for continuous tissue oxygen monitoring.

Profusa’s shares experienced a significant rally after the company announced a comprehensive debt restructuring aimed at reducing potential shareholder dilution and strengthening its balance sheet. The restructuring agreement involved exchanging existing obligations for new instruments with extended maturities and performance-linked terms. Management stated that this action will lower interest expense, improve liquidity through 2027 and position Profusa to execute its commercialization strategy without near-term funding constraints.